Business Standard

Thyrocare investors should exit given open offer discount to current price

Investors in Thyrocare should exit given the open offer discount to the current price

blood test
Premium

Thyrocare has been the best-performing diagnostics play with returns of 186 per cent over the past year.

Ram Prasad Sahu Mumbai
Investors in Thyrocare may not gain much by staying put in the company following the Rs 4,546-crore buyout of the promoter’s stake by API Holdings. The acquirer has also launched an open offer to buy 26 per cent stake in Thyrocare. 

“Given the current market price, which is at a 11 per cent premium to acquisition cost and open offer by API Holdings, investors in Thyrocare are better off selling their shares. The lack of clarity from the new management about the future course of action (offer for sale and delisting among others) is an additional risk for investors,” says Surajit

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in